Milano F, Emerson R O, Salit R, Guthrie K A, Thur L A, Dahlberg A, Robins H S, Delaney C
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States.
Front Oncol. 2020 Oct 9;10:583349. doi: 10.3389/fonc.2020.583349. eCollection 2020.
Cord blood transplantation (CBT) recipients are at increased risk of mortality due to delayed immune recovery (IR). Prior studies in CBT patients have shown that recovery of absolute lymphocyte count is predictive of survival after transplant. However, there are no data on the association of T-cell receptor (TCR) and clinical outcomes after CBT. Here we retrospectively performed TCR beta chain sequencing on peripheral blood (PB) samples of 34 CBT patients.
All patients received a total body irradiation based conditioning regimen and cyclosporine and MMF were used for graft host disease (GvHD) prophylaxis. PB was collected pretransplant on days 28, 56, 80, 180, and 1-year posttransplant for retrospective analysis of IR utilizing high-throughput sequencing of TCRβ rearrangements from genomic DNA extracted from PB mononuclear cells. To test the association between TCR repertoire diversity and patient outcomes, we conducted a permutation test on median TCR repertoire diversity for patients who died within the first year posttransplant those who survived.
Median age was 27 (range 1-58 years) and most of the patients (n = 27) had acute leukemias. There were 15 deaths occurring between 34 to 335 days after transplant. Seven deaths were due to relapse. Rapid turnover of T cell clones was observed at each time point, with TCR repertoires stabilizing by 1-year posttransplant. TCR diversity values at day 100 for patients who died between 100 and 365 days posttransplant were significantly lower than those of the surviving patients (p = 0.01).
Using a fast high-throughput TCR sequencing assay we have demonstrated that high TCR diversity is associated with better patient outcomes following CBT. Importantly, this assay is easily performed on posttransplant PB samples, even as early as day 28 posttransplant, making it an excellent candidate for early identification of patients at high risk of death.
由于免疫恢复延迟(IR),脐血移植(CBT)受者的死亡风险增加。先前对CBT患者的研究表明,绝对淋巴细胞计数的恢复可预测移植后的生存率。然而,尚无关于CBT后T细胞受体(TCR)与临床结局之间关联的数据。在此,我们对34例CBT患者的外周血(PB)样本进行了TCRβ链测序的回顾性研究。
所有患者均接受基于全身照射的预处理方案,并使用环孢素和霉酚酸酯预防移植物抗宿主病(GvHD)。在移植前、移植后第28天、56天、80天、180天和1年采集PB,用于利用从PB单核细胞提取的基因组DNA进行TCRβ重排的高通量测序对IR进行回顾性分析。为了测试TCR库多样性与患者结局之间的关联,我们对移植后第一年内死亡的患者和存活患者的中位TCR库多样性进行了置换检验。
中位年龄为27岁(范围1 - 58岁),大多数患者(n = 27)患有急性白血病。移植后34至335天之间有15例死亡。7例死亡归因于复发。在每个时间点均观察到T细胞克隆的快速更替,TCR库在移植后1年时稳定。移植后100至365天之间死亡的患者在第100天时的TCR多样性值显著低于存活患者(p = 0.01)。
使用快速高通量TCR测序分析,我们证明了高TCR多样性与CBT后更好的患者结局相关。重要的是,该分析即使在移植后第28天就可轻松在移植后的PB样本上进行,使其成为早期识别高死亡风险患者的极佳候选方法。